Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Recruiting now · Phase 3
Conditions studied: Relapsed or Refractory Large B-cell Lymphoma
In brief
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.
Key facts
- Study ID
- NCT07479797
- Run by
- Kite, A Gilead Company
- People needed
- 550
- Starts
- 2026-05-22
- Expected to finish
- 2031-05-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California, United States (enrolling)
- Stanford University — Stanford, California, United States (enrolling)
- Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
- Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta — Newnan, Georgia, United States (enrolling)
- Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States (enrolling)
- St. David's South Austin Medical Center — Austin, Texas, United States (enrolling)
- Epworth Healthcare — East Melbourne, Victoria, Australia (enrolling)
- Jewish General Hospital — Montreal, Canada (enrolling)
- McGill University Health Centre — Montreal, Canada (enrolling)
- CHU de Québec, Hôpital de l'Enfant-Jésus — Québec, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.